期刊文献+

2017年下半年美国FDA批准的新分子实体与评价:呼吸系统、感染和遗传病治疗药物

Updates of New Molecular Entities Approved by the FDA in the Second-Half of 2017: Drugs for Asthma, Infectious and Genetic Diseases
下载PDF
导出
摘要 2017年下半年FDA批准了23个新药,本系列文章对这些新药展开介绍和评价,本文将介绍呼吸系统、感染和遗传疾病治疗新药。 The US FDA approved 23 new molecular entities and new therapeutic biological products in the second-half of 2017. This article provides an update and evaluation of the new drugs approved for the treatment of asthma, infectious and genetic diseases.
作者 孙树森 赵志刚 SUN Shu-sen;ZHAO Zhi-gang(College of Pharmacy and Health Sciences,Western New England University,Springfield,MA 01119,United States;Department of Pharmacy,Beijing Tiantan Hospital Affliated to Capital Medical University,Beijing 100050,China)
出处 《药品评价》 CAS 2018年第18期3-8,共6页 Drug Evaluation
关键词 FDA 2017年下半年 新分子实体 呼吸系统疾病 感染病 遗传疾病 FDA 2017 New Molecular Entity Asthma Infectious Disease Genetic Diseases
  • 相关文献

二级参考文献19

  • 1PeytonL, Greene J. Irritable bowel syndrome: current and emerging treatment options[J]. PT, 2014, 39(8): 567-578.
  • 2Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review[J]. JAMA, 2015, 313(9): 949-958.
  • 3Paul C, Lacour J-P, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial(JUNCTURE)[J]. J EurAcad Dermatol VenereoL 2015, 29(6): 1082-1090.
  • 4Blaivelt A, Pfinz JC, Gottlieb AB, et al. Secukinumab administration by pm-fiUed syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis(FEATURE)[J]. Br J Dermatol, 2015, 172(2): 484-493.
  • 5Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results ot'cwo phase 3 trials[J]. N Engl J Med, 2014, 371(4): 326-338.
  • 6Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial[J]. J Am Acad Dermatol, 2015, 2015 Jun 16. pii: S0190-9622(15)01683-7. doi: 10. 1016/j. jaad. 2015.05.013. [Epub ahead of print].
  • 7脱氧胆酸药品说明书[OL].Kybella website.http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/2063330riglsOOOlbl.pdf.2015-4-29/2015.6.25.
  • 8Vazquez JA, Gonzalez Patzan LD, Stricklin D, et al. Efficacy and safety of ceiazidime-avibactamversus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study[J]. Curt Med Res Opin, 2012, 28(12): 1921-1931.
  • 9Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated inWa-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial[J]. J AnfimicrobChemother, 2013, 68(5): 1182-1192.
  • 10Me Cormack PL. Isavuconazonium: first global approval[J]. Drugs, 2015, 75: 817-822.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部